Following release of the final appraisal determination (FAD), the company, Bristol-Myers Squibb, has requested to submit an updated value proposition for nivolumab.
While we consider whether this value proposition can be put forward to the appraisal committee, we have suspended the FAD for consideration for appeal.
We will provide an update in due course to confirm the next steps for this appraisal.